Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meera Ramanujam

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Activated renal macrophages are markers of disease onset and disease remission in lupus nephritisLena Schiffer, Ramalingam Bethunaickan, Meera Ramanujam, et al.
The Journal of Clinical Investigation|February 18, 2006
Similarities and differences between selective and nonselective BAFF blockade in murine SLEMeera Ramanujam, Xiaobo Wang, Weiqing Huang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2012
Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritisCeline C Berthier, Ramalingam Bethunaickan, Tania Gonzalez-Rivera, et al.
Arthritis Research & Therapy|January 27, 2018
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupusSamantha A Chalmers, Jing Wen, Jessica Doerner, et al.
Scientific Reports|May 20, 2016
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine KinaseSamantha A Chalmers, Jessica Doerner, Todd Bosanac, et al.
British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2018
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritisSamantha A Chalmers, Elizabeth Glynn, Sayra J Garcia, et al.
Communications Biology|February 9, 2021
IL36 is a critical upstream amplifier of neutrophilic lung inflammation in miceCarolin K Koss, Christian T Wohnhaas, Jonathan R Baker, et al.
Annals of the Rheumatic Diseases|March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa studySudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
Arthritis and Rheumatism|June 12, 2013
Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinasePaola Mina-Osorio, Jacob LaStant, Natalie Keirstead, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Activated renal macrophages are markers of disease onset and disease remission in lupus nephritisLena Schiffer, Ramalingam Bethunaickan, Meera Ramanujam, et al.
The Journal of Clinical Investigation|February 18, 2006
Similarities and differences between selective and nonselective BAFF blockade in murine SLEMeera Ramanujam, Xiaobo Wang, Weiqing Huang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2012
Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritisCeline C Berthier, Ramalingam Bethunaickan, Tania Gonzalez-Rivera, et al.
Arthritis Research & Therapy|January 27, 2018
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupusSamantha A Chalmers, Jing Wen, Jessica Doerner, et al.
Scientific Reports|May 20, 2016
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine KinaseSamantha A Chalmers, Jessica Doerner, Todd Bosanac, et al.
British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2018
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritisSamantha A Chalmers, Elizabeth Glynn, Sayra J Garcia, et al.
Communications Biology|February 9, 2021
IL36 is a critical upstream amplifier of neutrophilic lung inflammation in miceCarolin K Koss, Christian T Wohnhaas, Jonathan R Baker, et al.
Annals of the Rheumatic Diseases|March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa studySudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
Arthritis and Rheumatism|June 12, 2013
Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinasePaola Mina-Osorio, Jacob LaStant, Natalie Keirstead, et al.
Pageof 4